Evidence map›Paper›PMID 41246306›Full record

ArticleFrontiers in immunology2025

Targeting Pin1 to overcome immunosuppressive tumor microenvironment in MSS colorectal cancer.

Jian Wang, Shuxin Tang, Jinhua Fan, Huihui Xiao, Shihua Wang, Jianqin Xiang, Zhili Liu, Hongying Liu, Zhigang Pei, Dequan Jiang and 8 more

Abstract read
In one paragraph

Article in Frontiers in immunology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 5 papers.

0numbers the graph read from it
0cells of the map it votes in
5citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

5 citing papers in PubMed.

  1. Review
  2. Review
  3. Article
  4. Article
  5. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

18 authors.

Jian Wang *Department of Oncology, Chongqing University Jiangjin Hospital, Chongqing, China.
Shuxin Tang *Department of Neonatology, The Sixth Affiliated Hospital, Sun Yat-sen University, Guangzhou, Guangdong, China.
Jinhua FanCentral Laboratory, Chongqing University Fuling Hospital, Chongqing University, Chongqing, China.
Huihui XiaoDepartment of Oncology, Chongqing University Jiangjin Hospital, Chongqing, China.
Shihua WangThe First Medicine College, Chongqing Medical University, Chongqing, China.
Jianqin XiangDepartment of Oncology, Chongqing University Jiangjin Hospital, Chongqing, China.
Zhili LiuDepartment of Cardiothoracic Surgery, Southwest Hospital Third Military Medical University, Chongqing, China.
Hongying LiuDepartment of Oncology, Chongqing University Jiangjin Hospital, Chongqing, China.
Zhigang PeiDepartment of Pathology, Chongqing University Jiangjin Hospital, Chongqing, China.
Dequan JiangDepartment of Gastrointestinal Surgery, Chongqing University Jiangjin Hospital, Chongqing, China.
Leiyuan ShuaiDepartment of Anus and Intestine Surgery, Chongqing University Jiangjin Hospital, Chongqing, China.
Han LiuDepartment of Ophthalmology, Chongqing University Jiangjin Hospital, Chongqing, China.
Jian YeDepartment of Anesthesiology, Chongqing University Jiangjin Hospital, Chongqing, China.
Jianli XuDepartment of Gastrointestinal Surgery, Chongqing University Jiangjin Hospital, Chongqing, China.
Chengyuan QianDepartment of Oncology, Chongqing University Jiangjin Hospital, Chongqing, China.
Siqian CuiDepartment of Oncology, Jiangjin Central Hospital of Chongqing, Chongqing, China.
Debing XiangDepartment of Oncology, Chongqing University Jiangjin Hospital, Chongqing, China.
Chunrong WuDepartment of Oncology, Chongqing University Jiangjin Hospital, Chongqing, China.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Background: Management of the immunosuppressive tumor microenvironment (TME) is crucial for microsatellite stability (MSS) colorectal cancer (CRC), which responds poorly to immunotherapy. PIN1, a peptidyl-prolyl cis-trans isomerase that is overexpressed in human malignancies, regulates TME immunosuppression. However, its role in MSS CRC remains insufficiently explored. Methods: We divided 411 CRC patients from the TCGA-COAD database into MSS or microsatellite instability-high (MSI-H) groups and analyzed their gene expression profiles. Using smoothed t-statistic SVM, weighted correlation network analysis, and sample clustering, we identified PIN1 as a key biomarker. We assessed Pin1 expression in CRC cell lines and tissues, and conducted functional assays, Results: PIN1 was overexpressed in MSS CRC and negatively correlated with CD4+ T and CD8+ T cell infiltration. Knockdown of PIN1 in MSS CRC cells significantly reduced cell proliferation (assessed by CCK-8 assay), impaired migratory capacity (assessed via wound-healing assay), and increased the apoptotic rate (detected by flow cytometry). In CT26 mouse models, combining Pin1 inhibition with PD-1 blockade enhanced immunotherapy efficacy by reducing Treg infiltration, suppressing cancer-associated fibroblast (CAF) activity, and promoting CD8+ T cell recruitment. Mechanistically, PIN1 activated the NF-κB pathway and modulated CCL3-CCR5 signaling, which are critical for Treg migration and CAF activation. Conclusion: Our findings suggest that Pin1 reshapes the immunosuppressive TME in MSS CRC through the NF-κB-CCL3-CCR5 axis, driving CRC progression and immunotherapy resistance. This pathway presents a potential target for overcoming immunotherapy resistance in MSS CRC.

Indexed as

Colorectal NeoplasmsNIMA-Interacting Peptidylprolyl IsomeraseTumor MicroenvironmentAnimalsCD8-Positive T-LymphocytesCell Line, TumorFemaleGene Expression Regulation, NeoplasticHumansLymphocytes, Tumor-InfiltratingMaleMiceNF-kappa BNF-kappa BNIMA-Interacting Peptidylprolyl IsomerasePIN1 protein, humanimmunosuppressive tumor microenvironment (TME)immunotherapy resistanceMSS colorectal cancer (CRC)NF-κB-CCL3-CCR5 axisPin1

Identifiers

PMID41246306
PMCPMC12615396

What Socratic holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.